While promising, these peptides remain experimental, highlighting the need for further studies to unlock their full potential in regenerative medicine
Studies as early as 1998 validate the use of correct oral treatment as being equally effective as injections, with a conclusion that stated: In cobalamin deficiency, 2,000mcg of cyanocobalamin administered orally on a daily basis was as effective and may be superior for raising blood B12 levels as 1,000mcg administered intramuscularly on a monthly basis
Additionally, if OCSCs are exposed to inflammatory mediators, undergo mesenchymal endothelial transformation, or experience dysregulation of the redox balance in the tumor microenvironment (TME), they may stimulate the continuous proliferation of OCSCs, potentially leading to OC development (63)
Thus, there is little data from which to draw conclusions about its safety, especially regarding long-term use in humans [2]